# A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Source: https://onco.cc/trials/nct07409428/  
OnCo record `nct07409428` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing HMPL-760 in diffuse large B-cell lymphoma, now recruiting.

## Summary

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL is a phase 3 interventional study registered as NCT07409428, led by Hutchmed, and recruiting on the registry. Official title: A Phase III Randomised, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Planned enrolment is 240 participants (estimated). The study started in 2026-03-20 and primary completion is expected in 2028-04-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07409428
- Phase: 3
- Setting: A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Sponsor: Hutchmed
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT07409428: https://clinicaltrials.gov/study/NCT07409428

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [HMPL-760](https://onco.cc/drugs/hmpl-760/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)

---
JSON: https://onco.cc/api/v1/entities/nct07409428.json